
Related topics: Regulatory & Safety, Globalisation, Lifecycle management, Mergers and acquisitions
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
Much of the discussion focused on the likely impact of the ongoing global economic downturn, the threat of biosimilars and US healthcare on biotechnology sector.
On a more positive note, Ernst & Young predicted that while the economic climate is difficult for biotechnology firms at the moment those that do survive are likely to do so due to effective business models, making for a stronger sector in years to come.
Another theme of the event was the importance of collaboration, both between biotech firms themselves and with players in the wider global pharmaceutical industry.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions
© 2012 - William Reed Business Media SAS - All rights reserved. ![]()